CHAMPIONS ONCOLOGY, INC. Q1 FY2027 earnings call

• Financial Discipline and Profitability: The company achieved its fifth consecutive quarter of positive adjusted EBITDA ($671,000), demonstrating improved operating leverage. Gross margin expanded to 50-51%, and the company continues to focus on converting revenue growth into profitability.
• Translational Oncology Services Strength: The core predictive modeling business remains healthy with strong demand. The quality of the tumor bank continues to be a key differentiator for customers. Management emphasizes that sales quality has improved, with higher conversion rates of contracted study values to recognized revenue.
• Data Licensing Growth: Revenue from data licensing surged, surpassing all of fiscal 2026's performance in Q1 FY27. This growth is attributed to a larger customer base built over the previous year. Management notes that while contracts are lumpy, the strategic case for deeply characterized, clinically annotated patient-derived data is strengthening as sponsors rely more on AI/ML.
• Corellia Strategic Positioning: As a wholly-owned therapeutic subsidiary, Corellia is actively engaging with venture groups and pharmaceutical partners. Management remains encouraged by external conversations and the data being generated, though no specific timeline for funding or licensing outcomes is provided.
• Operational Efficiency: Cost of oncology revenue decreased by approximately $500,000 due to bringing capabilities in-house, reducing reliance on expensive third-party services. R&D expenses were reduced to redirect resources toward Corellia and data initiatives.

The company reported total revenue of $15.2 million, an increase from $14 million in the first quarter of fiscal 2026. The Translational Oncology Services (TOS) business was the primary driver, generating $14.3 million in revenue. This segment achieved a gross margin of 51%, up significantly from 43% in the prior year period, driven by lower third-party radio labeling costs and operational leverage. Data licensing revenue contributed $893,000, which represents more data revenue in this single quarter than the entirety of fiscal 2026, reflecting a broader customer base. Corellia, the therapeutic subsidiary, is not yet generating significant standalone revenue but is focused on securing external funding or partnerships.

• No specific quantitative forward-looking guidance for full-year revenue or earnings was provided in this transcript.
• Management indicated confidence in the continued improvement of TOS margins and the trend of high conversion rates for new sales.
• Expectations remain that data licensing revenue will contribute positively, though it will likely remain lumpy due to contract timelines.
• The focus for the coming quarters is on maintaining expense discipline and expanding profitability while supporting investments in Corellia and data infrastructure.

• Revenue Lumpiness: Data licensing revenue is expected to remain lumpy as contracts close on their own timelines rather than on a predictable quarterly basis.
• Execution Risk on Corellia: There is uncertainty regarding the timeline and outcome of securing outside funding or licensing partnerships for the Corellia therapeutic subsidiary.
• Dependency on Key Personnel and Models: The TOS business relies heavily on proprietary clinical models and the quality of the tumor bank; any degradation in these assets could impact customer retention.
• Cash Flow Variability: The company utilized cash during the quarter due to working capital movements, including reductions in accounts payable and increases in accounts receivable, indicating potential volatility in short-term liquidity management.

Q: What drove the significant improvement in oncology services margin from 43% to 51%, and how sustainable is this cost reduction?

A: The margin expansion was primarily driven by a $500,000 decrease in the cost of oncology revenue, falling to $7.5 million despite revenue growth. This reduction resulted from lowering third-party radio labeling costs by bringing those capabilities in-house, creating a more efficient cost structure. Additionally, increased revenue volume contributed to margin improvement through operational leverage. Management expects this trend to continue as they maintain expense discipline.

Q: Can you elaborate on the drivers behind the surge in data licensing revenue, which exceeded all of fiscal 2026’s total in just one quarter?

A: The surge reflects the broader base of customers the company spent the last year building. While revenue is acknowledged to be lumpy due to varying contract timelines, the underlying demand is strong. Sponsors are increasingly relying on AI and machine learning, creating a constraint on high-quality, clinically annotated, patient-derived data. Champions possesses this scarce asset, allowing them to move beyond simple predictions to helping sponsors find signatures and design better trials.

Q: How is the company balancing investment in Corellia with the need for financial discipline in the core services business?

A: Management has deliberately redirected resources from the core services business toward Corellia and data initiatives, evidenced by a reduction in R&D expenses to $1.9 million from $2.1 million. Despite this shift, the core services business maintains strong sales quality and conversion rates. For Corellia, the strategy involves continuing external conversations with venture groups and pharma partners without committing to a specific timeline for funding or partnership outcomes, ensuring that current investments are protected while seeking strategic value.